Arrowhead entered into a license and collaboration agreement with Janssen in October 2018 to develop and commercialize ARO-HBV. Under the initial terms of the HBV license agreement, Arrowhead was eligible to receive a $50 million milestone payment linked to a Phase 2 study. Arrowhead and Janssen subsequently amended the HBV license agreement to accelerate the payment of $25 million of the $50 million Phase 2 milestone with the initiation of cohort 12 of the AROHBV1001 trial. Arrowhead is eligible to receive the remaining $25 million upon the initiation of a Phase 2 study by Janssen.
Is this the path Biotron may take. Especially considering the boards links to J&J. Not entering biotech showcase which they have for the past 10 years. Stephen coming on board as advisor I assume as this is his role with most other companies he is a part of. No update for nearly 6 months after reporting data from phase 2 trial. Is something actually in the works???
- Forums
- ASX - By Stock
- BIT
- The Glass is Half Full Thread.
The Glass is Half Full Thread., page-33
-
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BIT (ASX) to my watchlist
|
|||||
Last
4.0¢ |
Change
0.003(8.11%) |
Mkt cap ! $36.09M |
Open | High | Low | Value | Volume |
4.0¢ | 4.0¢ | 3.8¢ | $7.452K | 187.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 223754 | 3.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.0¢ | 236290 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 223754 | 0.038 |
4 | 632000 | 0.037 |
5 | 388512 | 0.036 |
6 | 753214 | 0.035 |
4 | 646000 | 0.033 |
Price($) | Vol. | No. |
---|---|---|
0.040 | 236290 | 2 |
0.041 | 230121 | 4 |
0.042 | 117600 | 1 |
0.043 | 432000 | 2 |
0.044 | 290000 | 2 |
Last trade - 15.32pm 04/07/2024 (20 minute delay) ? |
Featured News
BIT (ASX) Chart |